{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.45","upperLimit":"20.76","value":"15.05"},{"groupId":"OG001","lowerLimit":"7.85","upperLimit":"15.41","value":"10.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"title":"≥ 10 Mutations/MB"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.99","upperLimit":"19.98","value":"16.51"},{"groupId":"OG001","lowerLimit":"10.38","upperLimit":"14.92","value":"12.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"title":"< 10 Mutations/MB"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.34","upperLimit":"19.38","value":"15.57"},{"groupId":"OG001","lowerLimit":"10.35","upperLimit":"14.06","value":"12.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"237"},{"groupId":"OG001","value":"219"}],"units":"Participants"}],"title":"Overall"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.47","upperLimit":"25.49","value":"17.10"},{"groupId":"OG001","lowerLimit":"8.15","upperLimit":"11.79","value":"9.46"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"title":"Not Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"356"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab + Ipilimumab + Chemotherapy","id":"OG000","title":"Treatment A"},{"description":"Chemotherapy only","id":"OG001","title":"Treatment B"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants, Global Population with tumor mutational burden measurements","reportingStatus":"POSTED","timeFrame":"From date of randomization to date of death (assessed up to October 2024, approximately 72 months)","title":"OS by Tumor Mutational Burden","type":"SECONDARY","unitOfMeasure":"Months"}